ModifiedCentenePolicy CP.MP.162

Tandem Transplant

Medical necessity criteria and coding implications for planned tandem hematopoietic cell transplants across diagnoses including multiple myeloma, high-risk neuroblastoma, and relapsed/refractory testicular germ cell tumors; applies to Centene-affiliated health plan members/enrollees.

Policy Summary

PayerCentene

PolicyTandem Transplant

Policy CodePolicy CP.MP.162

Change TypeCriteria updates & HIV-related thresholds added

Effective Date

Next Review Date

Key ActionObtain prior authorization and document that the member meets all updated medical necessity criteria, including the revised contraindication checklist and HIV-related thresholds (CD4 >= 200, on effective ART, no active AIDS-defining infection).

SourceLink

POLICY UPDATE CHANGES

Replaced all previous contraindications (I.B.1 through 15) with a new contraindication list (I.B.1 through 6).

Added CD4 count, absence of active AIDS-defining opportunistic infection, and requirement for effective ART as transplantation contraindication considerations.

Updated neuroblastoma age-related criteria (I.A.3.b, c, d) to reflect months of age and previously from days.

Added substance use contraindication to I.B.1S.

Added criteria requiring CD4 count >= 200 cells/mm3, absence of active AIDS-defining opportunistic infection, and current effective ART for relevant candidates.

6current major contraindication items (I.B.1 - I.B.6)

3primary diagnoses explicitly discussed

Annual

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

policy review frequency

CP.MP.162policy identifier

CD4>=200explicit HIV-related threshold added

Coverage and Medical Necessity Criteria

Initial therapy / Indications

Covered when ALL of the following groups of criteria are met (per diagnosis-specific and general criteria):

General diagnosis and intent: Planned tandem autologous hematopoietic cell transplant: two planned high-dose HCTs within six months for specified diagnoses (examples include newly diagnosed or responsive multiple myeloma; high-risk neuroblastoma; relapsed or refractory testicular germ cell tumors).

See diagnosis-specific nodes for details.

Organ function and performance: Member does not have significant dysfunction of a major organ system or severe comorbidities (examples include: bilirubin <= 2 mg/dL; INR <= 1.6 unless on oral anticoagulants; ejection fraction >= 45% by MUGA or echocardiogram; FEV1 >= 50% predicted; DLCO >= 60% predicted; Karnofsky or Lansky score >= 70% or ECOG <= 2).

Referenced as contraindication screening.

Diagnosis-specific: Multiple Myeloma: Newly diagnosed or responsive multiple myeloma (MM). Tandem autologous HCT, and tandem autologous followed by reduced-intensity conditioning allogeneic HCT from an HLA-identical sibling donor, are medically necessary for untreated, newly diagnosed MM when no contraindications are present; unrelated donor allogeneic options considered case-by-case.

Per policy sections II and III.

Diagnosis-specific: Neuroblastoma: High-risk neuroblastoma by staging/risk stratification (INSS/INRG) including age- and MYCN-based criteria is a covered indication for tandem autologous transplants; age- and stage-based details are specified in policy I.A.3 (updated to months of age).

Policy references age- and stage-based nodes (I.A.3) for neuroblastoma.

Diagnosis-specific: Testicular germ cell tumor: Relapsed or refractory germ cell tumors, including platinum-refractory disease, are a covered indication for tandem or single high-dose chemotherapy with autologous SCT when medically necessary and evaluated at centers with expertise.

Policy includes testicular cancer among diagnoses eligible for tandem transplant.

Eligibility / Contraindications

Policy contains numbered eligibility and contraindication sections (references shown); candidates must meet the updated eligibility criteria and must not meet any listed contraindication items.

Candidate must meet updated eligibility and not meet contraindications: Candidates must satisfy the policy's eligibility criteria as updated (including diagnosis-specific items and the I.A. age/stage wording changes) and must NOT meet any contraindications listed in the current I.B.1 through I.B.6 list.

Full numbered eligibility and contraindication text appears in the policy (see I.A.x and I.B.1–6).

Specific contraindications (examples from policy text): Contraindications include, but are not limited to: uncontrolled or disseminated infection; acute liver failure (e.g., bilirubin > 2 mg/dL as an example organ dysfunction threshold); acute renal failure/shock; progressive cognitive impairment; substance use or inability to adhere to transplant regimen. Policy notes replacement of prior longer contraindication list with I.B.1–6 and addition of substance use as a contraindication.

Full contraindication list I.B.1–6 is in the document; examples and organ-failure thresholds are cited elsewhere in the policy.

HIV-related eligibility/contraindication handling:

As part of the 02/23 administrative revisions, the policy deliberately removed a prior broad exclusion (previously labeled as Criterion IV) that stated "current evidence does not support tandem transplants for any other indication than what is listed above." This change means the document no longer contains that blanket "not supported for other indications" statement in the exclusion section; coverage determinations should rely on the remaining diagnosis‑specific indications and updated eligibility/contraindication criteria.

Related to the same revision, the explicit sentence that "current evidence does not support tandem transplants for any other indication than what is listed above" was removed from the policy text. This is an administrative wording change noted in the revision log; clinicians and reviewers should therefore refer to the diagnosis‑specific coverage nodes and the updated contraindication list rather than relying on the removed blanket exclusion.

The policy identifies several clinical conditions that are exclusionary for tandem transplant evaluation. Examples called out in the revision history and contraindication updates include acute liver failure, acute renal failure or shock, and active extrapulmonary or disseminated infection. The document also lists progressive cognitive impairment and other severe uncontrolled medical conditions as reasons a candidate would be considered contraindicated.

Administratively, the revision notes remove the prior broad exclusion statement but the excerpted chunks do not reproduce a complete standalone "Not Medically Necessary" list. In other words, while the removal of Criterion IV is documented, these provided excerpts do not contain an explicit, separate NMN conditions list beyond the updated contraindication language shown elsewhere in the policy.

Candidate Selection and Specific Requirements

Prior Authorization

Prior authorization and documentation

Medical necessity and authorization requirements: Prior authorization is required for tandem autologous and tandem autologous → allogeneic transplants. Providers must document that the member meets diagnosis-specific indications (e.g., newly diagnosed or responsive multiple myeloma, select testicular cancers, high‑risk neuroblastoma per age/MYCN/histology criteria) and general fitness/organ function requirements (see candidate criteria). Authorization requests should include diagnostic evidence, prior treatment history, performance status, laboratory and organ function test results, infection status, and substance use assessment.

Prior Authorization

Tandem transplant prior authorization

Prior authorization is required specifically when requesting a tandem transplant (autologous→autologous or autologous→allogeneic). Requests for tandem autologous followed by allogeneic transplant from an HLA‑identical sibling with reduced‑intensity conditioning for untreated newly diagnosed multiple myeloma are covered when candidate criteria are met and no contraindications apply. Tandem autologous followed by allogeneic from an HLA‑compatible unrelated donor will be considered on a case‑by‑case basis and also requires prior authorization.

Contraindications and Reasons for Denial

The policy's contraindication section (updated/replaced during annual review) lists several specific exclusions, including acute liver failure; acute renal failure or shock; active extrapulmonary or disseminated infection; active tuberculosis infection; HIV infection with detectable viral load (unless meeting the updated HIV‑related criteria); and substance use or inability to adhere to the transplant regimen. These items are documented in the revision history as the key contraindications replacing the prior longer list.

Denial Risk

Contraindications and adherence risk screening

Screen and document presence or absence of listed contraindications and adherence risks; candidates with inadequate organ function, uncontrolled/disseminated infection, active tuberculosis, progressive cognitive impairment, substance use, or HIV with detectable viral load do not meet criteria.

Assess for acute liver failure, acute renal failure/shock, and other severe uncontrolled medical conditions.
Confirm no active extrapulmonary or disseminated infection or active tuberculosis.
Assess substance use and ability to adhere to post‑transplant regimen.

Denial Risk

Denial risk — noncompliance with updated contraindications

Prior Authorization, Documentation, and Billing Guidance

Prior Authorization

Prior authorization required — demonstrate medical necessity

Obtain prior authorization to demonstrate that the member meets all medical necessity criteria for a planned tandem autologous or tandem autologous → reduced‑intensity allogeneic transplant, including diagnosis, absence of contraindications, and donor compatibility when applicable.

Include documentation of diagnosis‑specific indications (e.g., MM, high‑risk neuroblastoma, relapsed/refractory testicular GCT).
Include evidence that none of the contraindications in I.B. are present.

Prior Authorization

Authorization expectation — document compliance with updated criteria

Prior authorization is required by policy governance; submit documentation that the candidate meets the updated policy criteria (including the current contraindication checklist and HIV‑related thresholds) as part of the authorization request.

Show eligibility against the updated criteria I.A and I.B (including I.B.1–6).
For planned autologous → allogeneic sequences, document donor HLA compatibility and conditioning intent.

Procedure Codes, Performance & Organ Function Metrics

Example transplant and harvesting CPT codes referencedCPT

38205	Blood-derived hematopoietic progenitor cell harvesting for transplantation, per collection; allogeneic.
38206	Blood-derived hematopoietic progenitor cell harvesting for transplantation, per collection; autologous.
38240	Hematopoietic progenitor cell (HPC) autologous transplantation.

No explicit CPT/HCPCS/ICD-10 codes in these chunksmixed

No codes listed

Performance status — required thresholds

Karnofsky or LanskyScore >= 70%

ECOGScore <= 2

ContextPerformance status listed as part of organ function and performance screening for tandem HCT candidates

Cardiac function — required thresholds

Ejection fraction (EF)>= 45% by MUGA scan or echocardiogram

Test methodsMultigated acquisition (MUGA) scan or echocardiogram are acceptable assessments

Post-Transplant Services and Coverage Considerations

Transplant-related global services — post-transplant coverage

Included services (examples)Pheresis and cell harvesting/collection procedures

Included servicesCell preparation and storage (cryopreservation)

Included servicesMarrow ablative (conditioning) therapy and supportive drugs/supplies

Included servicesHospitalization and outpatient follow-up care including medical/surgical, diagnostic, emergency, and rehabilitative services

Billing contextThese post-transplant global services are described within transplantation coding guidance (CPT code descriptions)

Tandem autologous and autologous/reduced-intensity allogeneic transplantation — references

Key Definitions

Tandem transplant — definition

DefinitionPlanned second course of high-dose therapy and hematopoietic cell transplant within six months of the first

SynonymsAlso called sequential or double transplant

DistinctionDistinct from repeat HCT because it is prospectively planned rather than performed for relapse

HSC/HPC collection — definition and timing

HSC collection timingCollected during recovery from induction chemotherapy or after filgrastim mobilization

HPC useHematopoietic progenitor cells collected during initial mobilization are used for subsequent transplant(s)

Background and Scope

Tandem transplant is defined as a planned second course of high‑dose therapy and hematopoietic cell transplant delivered within six months of the first procedure. The clinical rationale is that a scheduled second high‑dose/hematopoietic cell transplant (also called sequential or double transplant) can deepen and prolong response by eradicating residual tumor burden; the definition and intent apply across the spectrum of covered diagnoses referenced in the policy.

Facility and Program Expectations

Prior Authorization

Center requirements — multidisciplinary transplant expertise

Perform tandem transplants at centers with multidisciplinary transplant expertise; refer or document center capability and specialist involvement for complex indications such as testicular germ cell tumors.

Center should have experience with high‑dose chemotherapy and stem cell rescue and multidisciplinary support.
FACT accreditation or equivalent is implied by standard transplant expectations though not explicitly required in these excerpts.

Policy Changes and Review Notes

2024-02policy_revision

Added HIV-related evaluation thresholds: CD4 count >= 200 cells/mm3; absence of active AIDS-defining opportunistic infection; and requirement that the member is on effective antiretroviral therapy (ART).

2023-02policy_revision

Added substance use as a contraindication (I.B.1S) and removed criterion IV stating that tandem transplants are not supported for indications beyond those listed. Also updated verbiage in sections 1.3.b.ii, 1.3.c.i–iii, and LA.3.d.

2025-01-25annual_reviewLatest

Policy Summary

PayerCentene

PolicyTandem Transplant

Policy CodePolicy CP.MP.162

Change TypeCriteria updates & HIV-related thresholds added

Effective Date

Next Review Date

SourceLink

On This Page

For candidates with HIV or when HIV-related evaluation is applicable, the policy requires a CD4 cell count >= 200 cells/mm3 AND absence of active AIDS-defining opportunistic infection AND that the member is currently on effective antiretroviral therapy (ART); HIV with detectable viral load is otherwise considered a contraindication unless these criteria are met.

CD4 >= 200 cells/mm3

These HIV-specific items were added/clarified in the 02/24 and 01/25 annual reviews.

Denial Risk

Contraindications and adherence risks

Contraindications and adherence risks: Tandem transplantation is contraindicated in members with significant dysfunction of a major organ system or severe comorbidities (for example: bilirubin > 2 mg/dL; INR > 1.6 unless on oral anticoagulants; LVEF < 45%; FEV1 < 50% predicted; DLCO < 60% predicted), poor performance status (Karnofsky/Lansky ≤ 70% or ECOG > 2), uncontrolled or disseminated infection, active substance use that impairs adherence, or other conditions that would make transplant unsafe. For HIV‑infected candidates, additional requirements include CD4 count ≥ 200 cells/mm3, absence of active AIDS‑defining opportunistic infection, and the member being on effective antiretroviral therapy.

Denial Risk

Denials related to contraindications

Contraindication‑related denials: Requests will be denied when documented contraindications are present (eg, organ dysfunction thresholds, active uncontrolled infection, active substance use that precludes adherence, inadequate HIV control per the HIV‑specific thresholds). Ensure documentation addresses mitigation of risks and demonstrates medical appropriateness; absent sufficient documentation, the authorization may be denied.

Note

Sequencing and prior therapy documentation

Treatment sequencing context: Tandem transplants are intended in specified clinical scenarios (for example, tandem autologous ± subsequent allogeneic for select newly diagnosed or responsive multiple myeloma and other listed indications). The policy requires that tandem transplantation be considered in the context of prior lines of therapy and timing—providers must specify prior treatments, response status, and rationale for tandem sequencing versus single transplant or alternative therapies.

Note

Step therapy

No step therapy specifics are present in this policy section: there are no step‑therapy or required sequential medication trials mandated prior to authorization of tandem transplant in this policy.

Failure to comply with the policy's updated contraindication list (I.B.1 through I.B.6), including the newly added substance‑use contraindication, may result in denial of coverage for tandem transplant.

Policy replaced prior contraindications (I.B.1–15) with a new list I.B.1–6; document alignment with the current list.
Substance use was specifically added as a contraindication (I.B.1S).

Note

Treatment sequencing — contextual (no mandated step therapy)

The policy discusses sequencing (single vs tandem SCT and maintenance therapy) as context for clinical decision‑making but does not impose a mandated step‑therapy sequence; treatment sequencing decisions should be made clinically.

NCCN recommends collecting enough stem cells for two transplants when indicated; tandem transplant may be considered depending on response to first HCT and high‑risk features.
Policy does not require a specific sequence or maintenance algorithm as a coverage condition.

Step Therapy

Step therapy — none specified

No specific step‑therapy requirements are specified in the policy excerpts; there are no mandated prior‑treatment steps beyond meeting the listed medical necessity criteria.

Policy notes treatment sequencing considerations but provides no step‑therapy algorithm.

Billing Rule

Coding and documentation — include transplant procedure codes and supporting records

Submit appropriate procedure and transplant‑related CPT coding and supporting documentation with authorization and claims (e.g., HPC harvesting, transplantation, and related global services) per the policy's professional coding guidance.

Examples cited include CPT 38205, 38206, and 38240 and related transplant global service descriptions.
Include operative reports, harvest records, and documentation of pre/post‑transplant care when relevant.

Documentation Required

Document eligibility to updated criteria (including HIV thresholds)

Document candidate eligibility against the current policy language, including the updated contraindication list and the HIV‑specific thresholds (CD4 ≥ 200 cells/mm3, absence of active AIDS‑defining opportunistic infection, and being on effective ART) when applicable.

Note the replacement of previous contraindications with I.B.1–6 and record which items apply or are absent.
If HIV‑positive, document CD4 count, absence of AIDS‑defining infections, and current effective ART.

ContextCardiac function is part of major organ function contraindication screening

Pulmonary function — required thresholds

FEV1>= 50% of predicted

DLCO>= 60% of predicted

ContextPulmonary function thresholds used to determine fitness for tandem HCT

HIV / immunologic — required considerations

CD4 count (when applicable)>= 200 cells/mm3

Opportunistic infectionsAbsence of active AIDS-defining opportunistic infection

Antiretroviral therapy (ART)Member/enrollee currently on effective ART

CD4 cell count — explicit threshold

CD4 cell count threshold>= 200 cells/mm3

Policy noteCD4 threshold added to candidate/contraindication criteria during annual review

Related requirementsUsed with absence of active AIDS-defining infection and current effective ART to determine eligibility

Evidence and guidance referencedMultiple trials, COG studies, and guideline sources discussed supporting tandem approaches (e.g., neuroblastoma RCTs and MM studies)

Coverage rule specificsNo explicit duration or coverage-rule for post-transplant provided in cited chunks

Clinical contextPolicy references trials and guideline guidance when considering tandem autologous and autologous→reduced-intensity allogeneic sequences

Terminology distinctionDocument differentiates hematopoietic stem cells (HSCs) and hematopoietic progenitor cells (HPCs) in collection/use context

Tandem transplant (expanded) — procedural description

DescriptionSequential high-dose chemotherapy with one or more planned autologous (and in some schemas reduced-intensity allogeneic) HCT courses

PurposeUsed as consolidation for high-risk malignancies to improve depth and duration of response

Typical schemaSecond transplant planned prospectively within a defined period (commonly within six months) after the first

Annual review updated I.A.3.b,c,d to reflect months of age (instead of days) and replaced the prior contraindication list (I.B.1–15) with a new, shorter contraindication list (I.B.1–6); background and references were reviewed and updated.

Note

Change summary — document alignment with recent policy updates

Providers must note that the policy underwent administrative and material updates including replacement of the prior contraindication list with I.B.1–6, addition of HIV/CD4 criteria, and clarification of neuroblastoma age criteria; ensure submitted documentation reflects these revisions.

Replaced prior contraindications I.B.1–15 with new I.B.1–6.
Added CD4 ≥ 200 cells/mm3, absence of active AIDS‑defining infection, and current effective ART as HIV‑related candidate requirements.
Updated age‑related neuroblastoma criteria from days to months.